Status:
COMPLETED
Tolerance to Residual Astigmatism in Eyes With Vivity®
Lead Sponsor:
Clínica Rementería
Collaborating Sponsors:
Alcon Research
Conditions:
Lenses, Intraocular
Eligibility:
All Genders
40-90 years
Brief Summary
Low amounts of postoperative residual astigmatism may worsen the visual performance of patients implanted with presbyopia- correcting intraocular lenses (IOLs). Although extended depth of focus (EDoF)...
Detailed Description
Objectives: * Primary objective: To describe the tolerance of simulated astigmatism on patients implanted with Vivity at far distance. * Secondary objective: To describe the tolerance of simulated as...
Eligibility Criteria
Inclusion
- Patients \>40 years old that undergo routine cataract surgery
- Bilateral implantation of Vivity ® IOL
Exclusion
- Corneal astigmatism ≥1.0 diopters (D )
- Amblyopia
- Previous ocular surgery
- Presence of ocular pathologies
- Abnormal iris
- Patients with intra- or postoperative complications
- Postoperative best distance corrected visual acuity (BDCVA) \< 20/20
- Postoperative refractive astigmatism \> 0.50D
Key Trial Info
Start Date :
June 16 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 9 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05392998
Start Date
June 16 2021
End Date
March 9 2022
Last Update
March 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clínica Rementería
Madrid, Spain, 28010